# Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17

> **NCT00152009** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 345 (actual)

## Conditions studied

- Attention Deficit Disorder With Hyperactivity

## Interventions

- **DRUG:** SPD503 (Guanfacine hydrochloride) (2 mg)
- **DRUG:** SPD503 (3 mg)
- **DRUG:** SPD503 (4 mg)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00152009
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01-29
- **Primary completion:** 2003-08-23
- **Final completion:** 2003-08-23
- **Target enrollment:** 345 (ACTUAL)
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00152009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00152009, "Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00152009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*